Indications For Use
BIOVANCE 3L Ocular is an allograft intended for use as a biological membrane covering that provides an extracellular matrix. As a barrier membrane, BIOVANCE 3L Ocular is intended to protect the underlying tissue and preserve tissue plane boundaries. Applications include, but are not limited to, corneal and conjunctival related injuries or defects such as corneal epithelial defects, pterygium repair, fornix reconstruction, and other procedures.
BIOVANCE 3L Ocular is a pure human amniotic tissue with an intact basement membrane¹:
To learn more visit our Resources page
Cell attachment is a natural stimulus for the orderly release of growth factors and cytokines¹. An in vitro test was conducted to measure viability, adhesion, and proliferation of human corneal and conjunctival epithelial cells at days 1, 4 and 7².
With its unique 3-layer amnion basement membrane construction, BIOVANCE 3L Ocular is designed for superior handling and creating an optimal matrix for cell viability, adhesion, and proliferation, providing a cell-friendly environment as demonstrated in a comparative benchtop study²’³:
To learn more visit our Resources page
* ChAM=cryopreserved human amniotic membrane; DhAM=dehydrated human amniotic membrane
Biovance 3L Ocular is contraindicated in patients with a known hyper-sensitivity to BIOVANCE 3L Ocular. If a patient has an adverse reaction related to the use of BIOVANCE 3L Ocular, immediately discontinue its use. BIOVANCE 3L Ocular should not be used on clinically infected wounds. The pouch contents are sterile if the pouch is unopened and undamaged. Do not use if package seal is broken. Discard material if mishandling has caused possible damage or contamination. Do not resterilize. BIOVANCE 3L Ocular must be used prior to the expiration date on the product pouch. BIOVANCE 3L Ocular should not be used together with a collage-nase product on the wound.
————–
1. Bhatia M, Pereira M, Rana H, Stout B, Lewis C, Abramson S. The mechanism of cell interaction and response on decellularized human amniotic membrane: Implications in wound healing. 2007;19(8):207-217.
2. Diaz V. et al; ARVO2022 Poster; A Comparison Study of the Effects of Ocular Scaffolds on Human Ocular Epithelial Cells.
3. Mao Y, Protzman NM, John N, et al. An in vitro comparison of human corneal epithelial cell activity and inflammatory response on differently designed ocular amniotic membranes and a clinical case study. J Biomed Mater Res. 2022;1‐17. doi:10.1002/jbm.b.35186”
BIOVANCE® is a registered trademark of Celularity Inc. Verséa is a trademark of Verséa Health, Inc.
©2023 Verséa Health. All rights reserved.
© 2022 Verséa Health, Inc. All rights reserved.
Meet with the Verséa Ophthalmics team from June 21-24, 2023 at the Annual AOA Congress: Optometry’s Meeting® in Washington D.C. to learn more about how you can
We look forward to meeting with you at booth #1000!